<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03177603</url>
  </required_header>
  <id_info>
    <org_study_id>206246</org_study_id>
    <secondary_id>2017-000212-41</secondary_id>
    <nct_id>NCT03177603</nct_id>
  </id_info>
  <brief_title>A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH)</brief_title>
  <official_title>An Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2586881 in Participants With Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSK2586881, a purified intravenous (IV) formulation of soluble recombinant human Angiotensin
      Converting Enzyme (rhACE2) is being investigated as a treatment for PAH. This GlaxoSmithKline
      (GSK) study will evaluate the safety, tolerability, pharmacokinetics (PK) and
      pharmacodynamics (PD) of GSK2586881 in subjects with PAH. This open-label, dose-escalation
      study will comprise of 4 separate groups based on the planned dose range, and subjects in
      each group will be administered a single dose of GSK2586881 ranging between 0.1, 0.2, 0.4 and
      0.8 milligram per kilogram (mg/kg) via IV route. Dose escalation will occur after 4 subjects
      have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to
      24 hours post dose has taken place. A maximum of 27 subjects will be included in the study
      and the total duration of the study will be up to a maximum of 59 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 21, 2018</start_date>
  <completion_date type="Actual">May 7, 2019</completion_date>
  <primary_completion_date type="Actual">May 7, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Pulmonary Vascular Resistance (PVR)</measure>
    <time_frame>Baseline (Day 1, Pre-dose); 1 hour, 2 hours and 4 hours post-dose (Day 1)</time_frame>
    <description>PVR is the resistance generated by pulmonary circulation. Pulmonary arterial catheters were placed in participants and PVR values were recorded from the right heart catheterization. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Cardiac Output (CO)</measure>
    <time_frame>Baseline (Day 1, Pre-dose); 1 hour, 2 hours and 4 hours post-dose (Day 1)</time_frame>
    <description>CO is the amount of blood pumped by the heart per minute. Pulmonary arterial catheters were placed in participants and CO values were recorded from the right heart catheterization. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Mean Pulmonary Artery Pressure (mPAP)</measure>
    <time_frame>Baseline (Day 1, Pre-dose); 1 hour, 2 hours and 4 hours post-dose (Day 1)</time_frame>
    <description>The pulmonary artery pressure is a measure of the blood pressure found in the main pulmonary artery. Pulmonary arterial catheters were placed in participants and mPAP values were recorded from the right heart catheterization. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Non-serious Adverse Events (AEs)</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Any untoward event resulting in death, life threatening, requiring hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention were categorized as SAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphatase, Alanine Amino Transferase and Aspartate Amino Transferase</measure>
    <time_frame>Baseline (Day 1, Pre-dose), 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
    <description>Blood samples were collected for the assessment of clinical chemistry parameters: alkaline phosphatase, alanine amino transferase (ALT) and aspartate amino transferase (AST). Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Chemistry Parameters: Direct Bilirubin, Total Bilirubin and Creatinine</measure>
    <time_frame>Baseline (Day 1, Pre-dose), 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
    <description>Blood samples were collected for the assessment of clinical chemistry parameters: direct bilirubin, total bilirubin and creatinine. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Chemistry Parameters: Calcium, Glucose, Potassium, Sodium and Blood Urea Nitrogen (BUN)</measure>
    <time_frame>Baseline (Day 1, Pre-dose), 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
    <description>Blood samples were collected for the assessment of clinical chemistry parameters: calcium, glucose, potassium, sodium and BUN. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Chemistry Parameter: Total Protein</measure>
    <time_frame>Baseline (Day 1, Pre-dose), 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
    <description>Blood samples were collected for the assessment of clinical chemistry parameter, total protein. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count and White Blood Cell (WBC) Count</measure>
    <time_frame>Baseline (Day 1, Pre-dose), 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameters: basophils, eosinophils, lymphocytes, monocytes, total neutrophils (T.neutrophils), platelet count and WBC count. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Hemoglobin</measure>
    <time_frame>Baseline (Day 1, Pre-dose), 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameter, hemoglobin. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Hematocrit</measure>
    <time_frame>Baseline (Day 1, Pre-dose), 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameter, hematocrit. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Mean Corpuscle Hemoglobin</measure>
    <time_frame>Baseline (Day 1, Pre-dose), 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameter, mean corpuscle hemoglobin. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Mean Corpuscle Volume</measure>
    <time_frame>Baseline (Day 1, Pre-dose), 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameter, mean corpuscle volume. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Red Blood Cell (RBC) Count</measure>
    <time_frame>Baseline (Day 1, Pre-dose), 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameter: RBC count. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Reticulocytes</measure>
    <time_frame>Baseline (Day 1, Pre-dose), 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameter: reticulocytes. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Urinalysis Results by Dipstick Method</measure>
    <time_frame>24 hours post-dose (Day 1)</time_frame>
    <description>Urine samples were collected to assess urine bilirubin, urine occult blood, urine glucose, urine ketones, and urine protein by dipstick test. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameter of urine bilirubin, urine occult blood, urine glucose, urine ketones and urine protein can be read as negative, trace, 1+, 2+ and 3+ indicating proportional concentrations in the urine sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse Rate</measure>
    <time_frame>Baseline (Day 1, Pre-dose); 0.5 hour, 1 hour, 2 hours, 4 hours, 8 hours, 24 hours post-dose (Day 1); and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
    <description>Pulse rate was measured in supine position after at least a 5-minute rest. Change from Baseline in pulse rate was evaluated. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Respiratory Rate</measure>
    <time_frame>Baseline (Day 1, Pre-dose); 0.5 hour, 1 hour, 2 hours, 4 hours, 8 hours and 24 hours post-dose (Day 1); and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
    <description>Respiratory rate was measured in supine position after at least a 5-minute rest. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)</measure>
    <time_frame>Baseline (Day 1, Pre-dose); 0.5 hour, 1 hour, 2 hours, 4 hours, 8 hours and 24 hours post-dose (Day 1); and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
    <description>DBP and SBP were measured in supine position after at least a 5-minute rest. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Electrocardiogram (ECG) Findings</measure>
    <time_frame>4 hours and 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
    <description>12-lead ECGs were obtained at each time point using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and Corrected QT (QTc) intervals. Only those participants who had any abnormal ECG findings are presented. Abnormal ECG findings were categorized as clinically significant (CS) and not clinically significant (NCS) abnormal ECG findings. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse Oximetry Parameter: Percent Oxygen in Blood</measure>
    <time_frame>Baseline (Day 1, Pre-dose); 0.5 hour, 1 hour, 2 hours, 4 hours, 8 hours and 24 hours post-dose (Day 1); and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
    <description>Percent oxygen in blood was measured using pulse oximetry after the participant had rested for at least 5 minutes. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Immunogenicity Results</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Immunogenicity samples were collected into a serum-separating tube, mixed by gentle inversion 5 times and left to coagulate at room temperature for a minimum of 30 minutes and a maximum of 60 minutes. All samples were first tested for anti-angiotensin converting enzyme type 2 (ACE2) binding antibodies by screening and confirmation assay steps. If post-dose samples were found to be positive for anti-ACE2 binding antibodies, they would have been further characterized for anti-ACE2 neutralizing antibodies. Number of participants with positive immunogenicity results post-dosing are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systemic Renin-Angiotensin System (RAS) Peptides: Angiotensin II, Angiotensin (1-5) and Angiotensin (1-7)</measure>
    <time_frame>Baseline (Day 1, Pre-dose); 0.08 hour, 0.5 hour, 1 hour, 2 hours, 4 hours, 8 hours and 24 hours post-dose (Day 1); and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
    <description>Blood samples were collected to evaluate systemic RAS peptides: Angiotensin (Ang) II, Ang (1-7) and Ang (1-5). Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulmonary Wedge RAS Peptides: Angiotensin II, Angiotensin (1-5) and Angiotensin (1-7)</measure>
    <time_frame>Baseline (Day 1, Pre-dose); 1 hour, 2 hours and 4 hours post-dose (Day 1)</time_frame>
    <description>Blood samples were collected to evaluate pulmonary wedge RAS peptides: Ang II, Ang (1-5) and Ang (1-7). Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic RAS Peptide: Angiotensin II/Angiotensin (1-7) Ratio at Indicated Time Points</measure>
    <time_frame>0.08 hour, 0.5 hour, 1 hour, 2 hours, 4 hours, 8 hours and 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
    <description>Blood samples were collected to assess systemic RAS peptides: Angiotensin II and Angiotensin (1-7). Data for angiotensin II/angiotensin (1-7) ratio is presented. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Wedge RAS Peptide: Angiotensin II/Angiotensin (1-7) Ratio at Indicated Time Points</measure>
    <time_frame>1 hour, 2 hours and 4 hours post-dose (Day 1)</time_frame>
    <description>Blood samples were collected to assess pulmonary wedge RAS peptides: Angiotensin II and Angiotensin (1-7). Data for angiotensin II/angiotensin (1-7) ratio is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Biomarkers: N-terminal Pro B-type Natriuretic Peptide (NT Pro-BNP)</measure>
    <time_frame>Baseline (Day 1, Pre-dose); 2 hours, 4 hours and 24 hours post-dose (Day 1)</time_frame>
    <description>Blood samples were collected at specific time points to evaluate NT pro-BNP, a biomarker of disease activity. NT-pro-BNP is a biomarker of cardiac stress or ventricular workload and decreases as a result of reduced force of contraction if pulmonary blood pressure is reduced. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nitrite, Nitrate and Endogenous Nitrite (Biomarkers of Nitric Oxide [NO])</measure>
    <time_frame>Baseline (Day 1, Pre-dose); 2 hours, 4 hours and 24 hours post-dose (Day 1)</time_frame>
    <description>Blood samples were collected at specific time points to evaluate levels of nitrite, nitrate and endogenous nitrite (En. nitrite) (biomarkers of NO). Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Biomarker: Cardiac Troponin-I</measure>
    <time_frame>Baseline (Day 1, Pre-dose); 2 hours, 4 hours and 24 hours post-dose (Day 1)</time_frame>
    <description>Blood samples were collected at specific time points to assess cardiac troponin I. Cardiac troponin I is a biomarker of cardiac stress. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of GSK2586881</measure>
    <time_frame>Pre-dose (Day 1) and 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose (Day 1)</time_frame>
    <description>Blood samples were collected at indicated time points for evaluation of Cmax. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax) of GSK2586881</measure>
    <time_frame>Pre-dose (Day 1) and 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose (Day 1)</time_frame>
    <description>Blood samples were collected at indicated time points for evaluation of tmax. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-t]) of GSK2586881</measure>
    <time_frame>Pre-dose (Day 1) and 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose (Day 1)</time_frame>
    <description>Blood samples were collected at indicated time points for evaluation of AUC(0-t). Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) of GSK2586881</measure>
    <time_frame>Pre-dose (Day 1) and 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose (Day 1)</time_frame>
    <description>Blood samples were collected at indicated time points for evaluation of AUC(0-inf). Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Last Observed Quantifiable Concentration (Ct) of GSK2586881</measure>
    <time_frame>Pre-dose (Day 1) and 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose (Day 1)</time_frame>
    <description>Blood samples were collected at indicated time points for evaluation of Ct. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of the Last Quantifiable Concentration (Tlast) of GSK2586881</measure>
    <time_frame>Pre-dose (Day 1) and 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose (Day 1)</time_frame>
    <description>Blood samples were collected at indicated time points for evaluation of tlast. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Clearance (CL) of GSK2586881</measure>
    <time_frame>Pre-dose (Day 1) and 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose (Day 1)</time_frame>
    <description>Blood samples were collected at indicated time points for evaluation of CL. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution of GSK2586881</measure>
    <time_frame>Pre-dose (Day 1) and 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose (Day 1)</time_frame>
    <description>Blood samples were collected at indicated time points for evaluation of apparent volume of distribution. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Phase Half-life (t1/2) of GSK2586881</measure>
    <time_frame>Pre-dose (Day 1) and 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose (Day 1)</time_frame>
    <description>Blood samples were collected at indicated time points for evaluation of t1/2. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline in Cardiac Index (CI)</measure>
    <time_frame>Baseline (Day 1, Pre-dose); 1 hour, 2 hours and 4 hours post-dose (Day 1)</time_frame>
    <description>Cardiac index (CI) was measured using thermodilution. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>GSK2586881 - 0.1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive a single dose of 0.1 mg/kg GSK2586881. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2586881 - 0.2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive a single dose 0.2 mg/kg of GSK2586881 IV infusion. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2586881 - 0.4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive a single dose of 0.4 mg/kg of GSK2586881 IV infusion. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2586881 - 0.8 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive single dose of 0.8 mg/kg of GSK2586881 IV infusion. Dose escalation will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2586881</intervention_name>
    <description>GSK2586881 is a clear colorless liquid for IV infusion over 3- 5 minutes and will be administered a maximum dose of 0.8 mg/kg.</description>
    <arm_group_label>GSK2586881 - 0.1 mg/kg</arm_group_label>
    <arm_group_label>GSK2586881 - 0.2 mg/kg</arm_group_label>
    <arm_group_label>GSK2586881 - 0.4 mg/kg</arm_group_label>
    <arm_group_label>GSK2586881 - 0.8 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Subjects must be between 18-75 years of age (inclusive), at the time of signing the
             informed consent.

          -  Documented diagnosis of PAH, defined as mPAP &gt; 25 millimeter of mercury (mmHg) and
             pulmonary wedge pressure (PWP) &lt;= 15.

          -  Idiopathic PAH (IPAH), Hereditary PAH (HPAH), or PAH associated with collagen vascular
             disease, or appetite suppressant use.

          -  World Health Organization (WHO) functional class I, II, or III, stable for at least 8
             weeks prior to enrollment.

          -  Hemodynamically stable on background therapy with no evidence of uncontrolled right
             heart failure (historic data), as determined by the investigator.

          -  Six minute walk (6MW) distance, as performed at screening or within 6 months prior to
             screening, of &gt;= 100 meters (m) and &lt;= 500 m.

          -  Mean BP of &gt;60 mmHg.

          -  Receiving stable doses of one or more medications that are approved for treatment of
             PAH, including endothelin receptor antagonists, phosphodiesterase 5 inhibitors, and/or
             prostanoids/prostacyclin receptor agonists, for a minimum of 12 consecutive weeks
             before enrollment.

          -  Diuretic dose stable for 8 weeks.

          -  Body weight &lt;= 100 kg and body mass index (BMI) within the range 18-35 kg per m square
             (kg/m^2) (inclusive).

          -  Male and/or female (following confirmation of negative pregnancy test for Women of
             Childbearing Potential [WOCBP]). Women who are pregnant or breastfeeding are excluded.

          -  Capable of giving signed informed consent.

        Exclusion Criteria

          -  History of systemic hypotension, defined as systolic BP &lt;90 mmHg and/or diastolic BP
             &lt;50 mmHg.

          -  Hospitalization for PAH associated deterioration in the previous 6 months.

          -  Any additional medical condition, serious intercurrent illness, or other extenuating
             circumstance that, in the opinion of the Investigator, may significantly interfere
             with study compliance, including all prescribed evaluations and follow-up activities.
             Concurrent disease or condition that may interfere with study participation or safety
             include bleeding disorders, arrhythmia, organ transplant, organ failure, current
             neoplasm, poorly controlled diabetes mellitus, and serious neurological disorders.

          -  Complex repaired and unrepaired congenital heart disease.

          -  Subjects with Eisenmenger physiology.

          -  Alanine transferase (ALT) &gt;2x upper limit of normal (ULN).

          -  Bilirubin &gt;1.5xULN (isolated bilirubin &gt;1.5xULN is acceptable if bilirubin is
             fractionated and direct bilirubin &lt;35 percent).

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).

          -  Estimated glomerular-filtration-rate (eGFR) &lt;45 milliliter per minute per 1.73 meter
             square (mL/min/1.73m^2).

          -  QTc &gt;480 millisecond (msec) or QTc &gt; 500 msec in subjects with bundle branch block.

          -  Any bleeding concerns as evidenced by International normalized ratio (INR) &gt;1.5 (in
             subjects not receiving anticoagulation therapy) or platelet count &lt;80,000.

          -  Hemoglobin (Hb) &lt;10 gram per deciliter (g/dL).

          -  Sensitivity to any of the study treatments, or components thereof, or drug or other
             allergy that, in the opinion of the investigator or Medical Monitor, contraindicates
             participation in the study.

          -  Any use of an Angiotensin-converting enzyme (ACE) inhibitor or Angiotensin receptor
             blocker or renin inhibitors within 14 days prior to dosing. Therapy can be stopped to
             enable inclusion if deemed safe by the subject's treating physician.

          -  Use of any investigational product (IP) or device within 30 days prior to dosing, or
             known requirement for any investigational agent prior to completion of all scheduled
             study assessments.

          -  Positive human immunodeficiency virus (HIV) antibody test.

          -  Presence of Hepatitis B surface antigen (HBsAg) at screening.

          -  Positive Hepatitis C antibody test result at screening or within 3 months prior to
             starting study treatment.

          -  Positive Hepatitis C ribonucleic acid (RNA) test result at screening or within 3
             months prior to first dose of study treatment.

          -  Participation in the study would result in loss of blood or blood products in excess
             of 300mL within 65 days.

          -  Exposure to more than 4 new chemical entities within 12 months prior to the first
             dosing day.

          -  A known or suspected history of alcohol or drug abuse within the 2 years prior to
             screening.

          -  Unable to refrain from smoking during the in-house treatment period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2017</study_first_posted>
  <results_first_submitted>April 6, 2020</results_first_submitted>
  <results_first_submitted_qc>April 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 21, 2020</results_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Arterial Hypertension</keyword>
  <keyword>Dose-escalation</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>GSK2586881</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT03177603/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT03177603/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This phase 2a, open-label, dose-escalation study comprised of 4 cohorts. Participants received GSK2586881 by single intravenous (IV) infusion at following doses: 0.1 milligram per kilogram (mg/kg) or 0.2 mg/kg or 0.4 mg/kg or 0.8 mg/kg.</recruitment_details>
      <pre_assignment_details>A total of 31 participants were screened and of them 7 participants were screen failures and one withdrew consent before dosing. Hence, a total of 23 participants received study treatment. This study was conducted at 4 centers in Germany, 2 centers in Spain, and 2 centers in the United States.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GSK2586881 0.1 mg/kg</title>
          <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
        </group>
        <group group_id="P2">
          <title>GSK2586881 0.2 mg/kg</title>
          <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
        </group>
        <group group_id="P3">
          <title>GSK2586881 0.4 mg/kg</title>
          <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
        </group>
        <group group_id="P4">
          <title>GSK2586881 0.8 mg/kg</title>
          <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Cohort 1: Dose Level 0.1 mg/kg (28 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Cohort 2: Dose Level 0.2 mg/kg (28 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Cohort 3: Dose Level 0.4 mg/kg (28 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Cohort 4: Dose Level 0.8 mg/kg (28 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK2586881 0.1 mg/kg</title>
          <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
        </group>
        <group group_id="B2">
          <title>GSK2586881 0.2 mg/kg</title>
          <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
        </group>
        <group group_id="B3">
          <title>GSK2586881 0.4 mg/kg</title>
          <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
        </group>
        <group group_id="B4">
          <title>GSK2586881 0.8 mg/kg</title>
          <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.0" spread="4.97"/>
                    <measurement group_id="B2" value="55.4" spread="14.96"/>
                    <measurement group_id="B3" value="52.5" spread="8.67"/>
                    <measurement group_id="B4" value="50.3" spread="13.35"/>
                    <measurement group_id="B5" value="48.8" spread="13.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White - White/Caucasian/European Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Pulmonary Vascular Resistance (PVR)</title>
        <description>PVR is the resistance generated by pulmonary circulation. Pulmonary arterial catheters were placed in participants and PVR values were recorded from the right heart catheterization. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value.</description>
        <time_frame>Baseline (Day 1, Pre-dose); 1 hour, 2 hours and 4 hours post-dose (Day 1)</time_frame>
        <population>Evaluable Population comprised of all participants who were in the safety population, who completed all Day 1 assessments (including up to 24 hours post dose) and were not deemed to have had major protocol deviations. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulmonary Vascular Resistance (PVR)</title>
          <description>PVR is the resistance generated by pulmonary circulation. Pulmonary arterial catheters were placed in participants and PVR values were recorded from the right heart catheterization. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value.</description>
          <population>Evaluable Population comprised of all participants who were in the safety population, who completed all Day 1 assessments (including up to 24 hours post dose) and were not deemed to have had major protocol deviations. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.936" lower_limit="0.725" upper_limit="1.208"/>
                    <measurement group_id="O2" value="0.885" lower_limit="0.686" upper_limit="1.141"/>
                    <measurement group_id="O3" value="0.813" lower_limit="0.561" upper_limit="1.178"/>
                    <measurement group_id="O4" value="1.017" lower_limit="0.862" upper_limit="1.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.926" lower_limit="0.671" upper_limit="1.279"/>
                    <measurement group_id="O2" value="1.043" lower_limit="0.910" upper_limit="1.195"/>
                    <measurement group_id="O3" value="0.945" lower_limit="0.788" upper_limit="1.134"/>
                    <measurement group_id="O4" value="0.974" lower_limit="0.823" upper_limit="1.153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.907" lower_limit="0.552" upper_limit="1.490"/>
                    <measurement group_id="O2" value="0.895" lower_limit="0.668" upper_limit="1.199"/>
                    <measurement group_id="O3" value="0.924" lower_limit="0.589" upper_limit="1.448"/>
                    <measurement group_id="O4" value="1.116" lower_limit="1.050" upper_limit="1.186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Cardiac Output (CO)</title>
        <description>CO is the amount of blood pumped by the heart per minute. Pulmonary arterial catheters were placed in participants and CO values were recorded from the right heart catheterization. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value.</description>
        <time_frame>Baseline (Day 1, Pre-dose); 1 hour, 2 hours and 4 hours post-dose (Day 1)</time_frame>
        <population>Evaluable Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cardiac Output (CO)</title>
          <description>CO is the amount of blood pumped by the heart per minute. Pulmonary arterial catheters were placed in participants and CO values were recorded from the right heart catheterization. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value.</description>
          <population>Evaluable Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.046" lower_limit="0.881" upper_limit="1.240"/>
                    <measurement group_id="O2" value="1.079" lower_limit="0.966" upper_limit="1.206"/>
                    <measurement group_id="O3" value="1.076" lower_limit="0.758" upper_limit="1.528"/>
                    <measurement group_id="O4" value="0.990" lower_limit="0.948" upper_limit="1.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.025" lower_limit="0.829" upper_limit="1.269"/>
                    <measurement group_id="O2" value="1.029" lower_limit="0.950" upper_limit="1.116"/>
                    <measurement group_id="O3" value="0.929" lower_limit="0.712" upper_limit="1.210"/>
                    <measurement group_id="O4" value="1.012" lower_limit="0.944" upper_limit="1.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.114" lower_limit="0.804" upper_limit="1.545"/>
                    <measurement group_id="O2" value="1.138" lower_limit="0.949" upper_limit="1.365"/>
                    <measurement group_id="O3" value="0.882" lower_limit="0.734" upper_limit="1.060"/>
                    <measurement group_id="O4" value="1.002" lower_limit="0.935" upper_limit="1.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Pulmonary Artery Pressure (mPAP)</title>
        <description>The pulmonary artery pressure is a measure of the blood pressure found in the main pulmonary artery. Pulmonary arterial catheters were placed in participants and mPAP values were recorded from the right heart catheterization. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value.</description>
        <time_frame>Baseline (Day 1, Pre-dose); 1 hour, 2 hours and 4 hours post-dose (Day 1)</time_frame>
        <population>Evaluable Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Pulmonary Artery Pressure (mPAP)</title>
          <description>The pulmonary artery pressure is a measure of the blood pressure found in the main pulmonary artery. Pulmonary arterial catheters were placed in participants and mPAP values were recorded from the right heart catheterization. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value.</description>
          <population>Evaluable Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.950" lower_limit="0.781" upper_limit="1.154"/>
                    <measurement group_id="O2" value="0.995" lower_limit="0.960" upper_limit="1.032"/>
                    <measurement group_id="O3" value="0.939" lower_limit="0.799" upper_limit="1.104"/>
                    <measurement group_id="O4" value="0.989" lower_limit="0.879" upper_limit="1.114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.937" lower_limit="0.781" upper_limit="1.126"/>
                    <measurement group_id="O2" value="0.994" lower_limit="0.924" upper_limit="1.070"/>
                    <measurement group_id="O3" value="0.910" lower_limit="0.766" upper_limit="1.081"/>
                    <measurement group_id="O4" value="0.996" lower_limit="0.867" upper_limit="1.144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.991" lower_limit="0.812" upper_limit="1.211"/>
                    <measurement group_id="O2" value="1.029" lower_limit="0.881" upper_limit="1.202"/>
                    <measurement group_id="O3" value="0.973" lower_limit="0.897" upper_limit="1.054"/>
                    <measurement group_id="O4" value="1.062" lower_limit="0.958" upper_limit="1.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Non-serious Adverse Events (AEs)</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>Safety Population comprised of all participants who took at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-serious Adverse Events (AEs)</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.</description>
          <population>Safety Population comprised of all participants who took at least 1 dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events (SAEs)</title>
        <description>Any untoward event resulting in death, life threatening, requiring hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention were categorized as SAE.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAEs)</title>
          <description>Any untoward event resulting in death, life threatening, requiring hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention were categorized as SAE.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphatase, Alanine Amino Transferase and Aspartate Amino Transferase</title>
        <description>Blood samples were collected for the assessment of clinical chemistry parameters: alkaline phosphatase, alanine amino transferase (ALT) and aspartate amino transferase (AST). Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
        <time_frame>Baseline (Day 1, Pre-dose), 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphatase, Alanine Amino Transferase and Aspartate Amino Transferase</title>
          <description>Blood samples were collected for the assessment of clinical chemistry parameters: alkaline phosphatase, alanine amino transferase (ALT) and aspartate amino transferase (AST). Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
          <population>Safety Population</population>
          <units>International units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alkaline phosphatase, 24 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="8.42"/>
                    <measurement group_id="O2" value="-1.4" spread="7.44"/>
                    <measurement group_id="O3" value="5.3" spread="3.08"/>
                    <measurement group_id="O4" value="3.1" spread="3.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase, Day 7 to Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="5.00"/>
                    <measurement group_id="O2" value="3.2" spread="4.21"/>
                    <measurement group_id="O3" value="3.0" spread="3.52"/>
                    <measurement group_id="O4" value="2.6" spread="4.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, 24 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="2.16"/>
                    <measurement group_id="O2" value="0.0" spread="1.58"/>
                    <measurement group_id="O3" value="-1.8" spread="3.76"/>
                    <measurement group_id="O4" value="-0.1" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Day 7 to Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.96"/>
                    <measurement group_id="O2" value="1.8" spread="3.27"/>
                    <measurement group_id="O3" value="-4.3" spread="12.94"/>
                    <measurement group_id="O4" value="0.9" spread="4.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, 24 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.63"/>
                    <measurement group_id="O2" value="-0.4" spread="0.55"/>
                    <measurement group_id="O3" value="0.5" spread="1.76"/>
                    <measurement group_id="O4" value="-1.8" spread="3.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Day 7 to Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="2.50"/>
                    <measurement group_id="O2" value="1.4" spread="1.67"/>
                    <measurement group_id="O3" value="-0.3" spread="3.67"/>
                    <measurement group_id="O4" value="-0.9" spread="6.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinical Chemistry Parameters: Direct Bilirubin, Total Bilirubin and Creatinine</title>
        <description>Blood samples were collected for the assessment of clinical chemistry parameters: direct bilirubin, total bilirubin and creatinine. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
        <time_frame>Baseline (Day 1, Pre-dose), 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Chemistry Parameters: Direct Bilirubin, Total Bilirubin and Creatinine</title>
          <description>Blood samples were collected for the assessment of clinical chemistry parameters: direct bilirubin, total bilirubin and creatinine. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
          <population>Safety Population</population>
          <units>Micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Direct bilirubin, 24 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.63"/>
                    <measurement group_id="O2" value="0.4" spread="0.89"/>
                    <measurement group_id="O3" value="0.3" spread="1.97"/>
                    <measurement group_id="O4" value="1.0" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct bilirubin, Day 7 to Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.15"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="1.26"/>
                    <measurement group_id="O4" value="0.5" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin, 24 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="4.16"/>
                    <measurement group_id="O2" value="0.8" spread="1.79"/>
                    <measurement group_id="O3" value="0.7" spread="4.84"/>
                    <measurement group_id="O4" value="4.8" spread="6.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin, Day 7 to Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="3.42"/>
                    <measurement group_id="O2" value="0.4" spread="2.61"/>
                    <measurement group_id="O3" value="-1.7" spread="3.44"/>
                    <measurement group_id="O4" value="0.0" spread="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, 24 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.08" spread="4.102"/>
                    <measurement group_id="O2" value="10.80" spread="6.110"/>
                    <measurement group_id="O3" value="12.22" spread="20.214"/>
                    <measurement group_id="O4" value="1.76" spread="2.759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, Day 7 to Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.12" spread="6.530"/>
                    <measurement group_id="O2" value="8.68" spread="13.353"/>
                    <measurement group_id="O3" value="4.57" spread="9.638"/>
                    <measurement group_id="O4" value="3.20" spread="4.885"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinical Chemistry Parameters: Calcium, Glucose, Potassium, Sodium and Blood Urea Nitrogen (BUN)</title>
        <description>Blood samples were collected for the assessment of clinical chemistry parameters: calcium, glucose, potassium, sodium and BUN. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
        <time_frame>Baseline (Day 1, Pre-dose), 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Chemistry Parameters: Calcium, Glucose, Potassium, Sodium and Blood Urea Nitrogen (BUN)</title>
          <description>Blood samples were collected for the assessment of clinical chemistry parameters: calcium, glucose, potassium, sodium and BUN. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
          <population>Safety Population</population>
          <units>Millimoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium, 24 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.035" spread="0.1427"/>
                    <measurement group_id="O2" value="0.012" spread="0.0867"/>
                    <measurement group_id="O3" value="0.047" spread="0.1033"/>
                    <measurement group_id="O4" value="0.060" spread="0.0466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, Day 7 to Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" spread="0.1399"/>
                    <measurement group_id="O2" value="0.064" spread="0.0888"/>
                    <measurement group_id="O3" value="0.047" spread="0.1250"/>
                    <measurement group_id="O4" value="0.115" spread="0.0583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 24 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="0.957"/>
                    <measurement group_id="O2" value="1.10" spread="1.398"/>
                    <measurement group_id="O3" value="0.50" spread="1.752"/>
                    <measurement group_id="O4" value="0.89" spread="2.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Day 7 to Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="1.760"/>
                    <measurement group_id="O2" value="-0.32" spread="0.646"/>
                    <measurement group_id="O3" value="-0.57" spread="0.635"/>
                    <measurement group_id="O4" value="-0.20" spread="1.995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, 24 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.377"/>
                    <measurement group_id="O2" value="0.18" spread="0.179"/>
                    <measurement group_id="O3" value="0.08" spread="0.306"/>
                    <measurement group_id="O4" value="-0.05" spread="0.239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, Day 7 to Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.356"/>
                    <measurement group_id="O2" value="0.22" spread="0.148"/>
                    <measurement group_id="O3" value="0.25" spread="0.207"/>
                    <measurement group_id="O4" value="0.18" spread="0.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, 24 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="1.26"/>
                    <measurement group_id="O2" value="-0.6" spread="2.30"/>
                    <measurement group_id="O3" value="-0.2" spread="1.47"/>
                    <measurement group_id="O4" value="-1.0" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, Day 7 to Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="4.19"/>
                    <measurement group_id="O2" value="0.0" spread="1.87"/>
                    <measurement group_id="O3" value="0.5" spread="1.64"/>
                    <measurement group_id="O4" value="0.0" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN, 24 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="1.080"/>
                    <measurement group_id="O2" value="-0.20" spread="0.758"/>
                    <measurement group_id="O3" value="0.83" spread="1.033"/>
                    <measurement group_id="O4" value="-0.25" spread="0.463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN, Day 7 to Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="1.258"/>
                    <measurement group_id="O2" value="1.50" spread="1.541"/>
                    <measurement group_id="O3" value="0.00" spread="1.000"/>
                    <measurement group_id="O4" value="0.31" spread="1.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinical Chemistry Parameter: Total Protein</title>
        <description>Blood samples were collected for the assessment of clinical chemistry parameter, total protein. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
        <time_frame>Baseline (Day 1, Pre-dose), 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Chemistry Parameter: Total Protein</title>
          <description>Blood samples were collected for the assessment of clinical chemistry parameter, total protein. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
          <population>Safety Population</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="6.13"/>
                    <measurement group_id="O2" value="0.6" spread="3.78"/>
                    <measurement group_id="O3" value="1.8" spread="2.93"/>
                    <measurement group_id="O4" value="2.6" spread="3.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 to Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="2.38"/>
                    <measurement group_id="O2" value="6.2" spread="4.55"/>
                    <measurement group_id="O3" value="2.0" spread="4.73"/>
                    <measurement group_id="O4" value="4.9" spread="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count and White Blood Cell (WBC) Count</title>
        <description>Blood samples were collected for the assessment of hematology parameters: basophils, eosinophils, lymphocytes, monocytes, total neutrophils (T.neutrophils), platelet count and WBC count. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
        <time_frame>Baseline (Day 1, Pre-dose), 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count and White Blood Cell (WBC) Count</title>
          <description>Blood samples were collected for the assessment of hematology parameters: basophils, eosinophils, lymphocytes, monocytes, total neutrophils (T.neutrophils), platelet count and WBC count. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
          <units>Giga cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils, 24 hours post-dose (Day 1), n=4,4,6,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.008" spread="0.0359"/>
                    <measurement group_id="O2" value="0.013" spread="0.0206"/>
                    <measurement group_id="O3" value="-0.005" spread="0.0302"/>
                    <measurement group_id="O4" value="0.003" spread="0.0115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, Day 7 to Day 14, n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.0327"/>
                    <measurement group_id="O2" value="0.002" spread="0.0192"/>
                    <measurement group_id="O3" value="0.008" spread="0.0306"/>
                    <measurement group_id="O4" value="0.003" spread="0.0238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, 24 hours post-dose (Day 1), n=4,4,6,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007" spread="0.0695"/>
                    <measurement group_id="O2" value="0.018" spread="0.0222"/>
                    <measurement group_id="O3" value="0.012" spread="0.0662"/>
                    <measurement group_id="O4" value="-0.007" spread="0.0503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Day 7 to Day 14, n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.035" spread="0.0835"/>
                    <measurement group_id="O2" value="0.004" spread="0.0230"/>
                    <measurement group_id="O3" value="-0.025" spread="0.0807"/>
                    <measurement group_id="O4" value="0.023" spread="0.1004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, 24 hours post-dose (Day 1), n=4,4,6,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.5509"/>
                    <measurement group_id="O2" value="-0.070" spread="0.1612"/>
                    <measurement group_id="O3" value="-0.157" spread="0.1558"/>
                    <measurement group_id="O4" value="0.190" spread="0.4553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, Day 7 to Day 14, n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.025" spread="0.4277"/>
                    <measurement group_id="O2" value="-0.054" spread="0.1422"/>
                    <measurement group_id="O3" value="-0.250" spread="0.2001"/>
                    <measurement group_id="O4" value="0.130" spread="0.4032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, 24 hours post-dose (Day 1), n=4,4,6,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.050" spread="0.0673"/>
                    <measurement group_id="O2" value="-0.028" spread="0.0914"/>
                    <measurement group_id="O3" value="0.098" spread="0.1125"/>
                    <measurement group_id="O4" value="0.140" spread="0.0700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, Day 7 to Day 14, n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.038" spread="0.1066"/>
                    <measurement group_id="O2" value="0.038" spread="0.0998"/>
                    <measurement group_id="O3" value="0.047" spread="0.1263"/>
                    <measurement group_id="O4" value="0.091" spread="0.1654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T.neutrophils, 24 hours post-dose(Day1),n=4,4,6,3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.643" spread="1.0052"/>
                    <measurement group_id="O2" value="0.415" spread="0.3924"/>
                    <measurement group_id="O3" value="0.738" spread="0.5615"/>
                    <measurement group_id="O4" value="0.727" spread="0.7298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T.neutrophils, Day 7 to Day 14, n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.185" spread="0.9008"/>
                    <measurement group_id="O2" value="0.504" spread="0.4884"/>
                    <measurement group_id="O3" value="0.397" spread="1.3173"/>
                    <measurement group_id="O4" value="0.366" spread="0.7204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, 24 hours post-dose (Day 1), n=4,4,6,5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="36.28"/>
                    <measurement group_id="O2" value="-33.0" spread="73.51"/>
                    <measurement group_id="O3" value="7.8" spread="16.65"/>
                    <measurement group_id="O4" value="12.6" spread="27.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, Day 7 to Day 14, n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3" spread="17.40"/>
                    <measurement group_id="O2" value="19.8" spread="45.03"/>
                    <measurement group_id="O3" value="14.3" spread="52.89"/>
                    <measurement group_id="O4" value="23.4" spread="24.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC count, 24 hours post-dose (Day 1), n=4,4,6,5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="1.330"/>
                    <measurement group_id="O2" value="0.30" spread="0.183"/>
                    <measurement group_id="O3" value="0.68" spread="0.542"/>
                    <measurement group_id="O4" value="2.16" spread="2.492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC count, Day 7 to Day 14, n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="1.334"/>
                    <measurement group_id="O2" value="0.46" spread="0.498"/>
                    <measurement group_id="O3" value="0.20" spread="1.355"/>
                    <measurement group_id="O4" value="0.64" spread="0.588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology Parameter: Hemoglobin</title>
        <description>Blood samples were collected for the assessment of hematology parameter, hemoglobin. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
        <time_frame>Baseline (Day 1, Pre-dose), 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Hemoglobin</title>
          <description>Blood samples were collected for the assessment of hematology parameter, hemoglobin. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 hours post-dose (Day 1), n=4,4,6,5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="11.09"/>
                    <measurement group_id="O2" value="2.0" spread="5.72"/>
                    <measurement group_id="O3" value="5.0" spread="4.77"/>
                    <measurement group_id="O4" value="3.0" spread="5.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 to Day 14, n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="6.55"/>
                    <measurement group_id="O2" value="3.4" spread="5.98"/>
                    <measurement group_id="O3" value="-1.5" spread="7.09"/>
                    <measurement group_id="O4" value="4.0" spread="5.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology Parameter: Hematocrit</title>
        <description>Blood samples were collected for the assessment of hematology parameter, hematocrit. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
        <time_frame>Baseline (Day 1, Pre-dose), 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Hematocrit</title>
          <description>Blood samples were collected for the assessment of hematology parameter, hematocrit. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
          <units>Proportion of red blood cells in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 hours post-dose (Day 1), n=4,4,6,5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0030" spread="0.02858"/>
                    <measurement group_id="O2" value="0.0053" spread="0.02156"/>
                    <measurement group_id="O3" value="0.0098" spread="0.01546"/>
                    <measurement group_id="O4" value="0.0140" spread="0.02448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 to Day 14, n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0225" spread="0.00929"/>
                    <measurement group_id="O2" value="0.0104" spread="0.02173"/>
                    <measurement group_id="O3" value="0.0030" spread="0.02391"/>
                    <measurement group_id="O4" value="0.0135" spread="0.01891"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology Parameter: Mean Corpuscle Hemoglobin</title>
        <description>Blood samples were collected for the assessment of hematology parameter, mean corpuscle hemoglobin. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
        <time_frame>Baseline (Day 1, Pre-dose), 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Mean Corpuscle Hemoglobin</title>
          <description>Blood samples were collected for the assessment of hematology parameter, mean corpuscle hemoglobin. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
          <units>Picograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 hours post-dose (Day 1), n=4,4,6,5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.150"/>
                    <measurement group_id="O2" value="0.05" spread="0.507"/>
                    <measurement group_id="O3" value="0.25" spread="0.302"/>
                    <measurement group_id="O4" value="-0.10" spread="0.235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 to Day 14, n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.483"/>
                    <measurement group_id="O2" value="0.04" spread="0.182"/>
                    <measurement group_id="O3" value="-0.33" spread="0.314"/>
                    <measurement group_id="O4" value="0.15" spread="0.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology Parameter: Mean Corpuscle Volume</title>
        <description>Blood samples were collected for the assessment of hematology parameter, mean corpuscle volume. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
        <time_frame>Baseline (Day 1, Pre-dose), 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Mean Corpuscle Volume</title>
          <description>Blood samples were collected for the assessment of hematology parameter, mean corpuscle volume. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
          <units>Femtoliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 hours post-dose (Day 1), n=4,4,6,5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="2.52"/>
                    <measurement group_id="O2" value="0.0" spread="0.82"/>
                    <measurement group_id="O3" value="-0.5" spread="0.84"/>
                    <measurement group_id="O4" value="0.6" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 to Day 14, n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="2.08"/>
                    <measurement group_id="O2" value="-0.2" spread="0.84"/>
                    <measurement group_id="O3" value="0.7" spread="1.03"/>
                    <measurement group_id="O4" value="0.8" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology Parameter: Red Blood Cell (RBC) Count</title>
        <description>Blood samples were collected for the assessment of hematology parameter: RBC count. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
        <time_frame>Baseline (Day 1, Pre-dose), 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Red Blood Cell (RBC) Count</title>
          <description>Blood samples were collected for the assessment of hematology parameter: RBC count. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
          <units>Trillion cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 hours post-dose (Day 1), n=4,4,6,5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.435"/>
                    <measurement group_id="O2" value="0.03" spread="0.287"/>
                    <measurement group_id="O3" value="0.13" spread="0.163"/>
                    <measurement group_id="O4" value="0.12" spread="0.192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 to Day 14, n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.183"/>
                    <measurement group_id="O2" value="0.14" spread="0.261"/>
                    <measurement group_id="O3" value="0.00" spread="0.310"/>
                    <measurement group_id="O4" value="0.11" spread="0.203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology Parameter: Reticulocytes</title>
        <description>Blood samples were collected for the assessment of hematology parameter: reticulocytes. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
        <time_frame>Baseline (Day 1, Pre-dose), 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Reticulocytes</title>
          <description>Blood samples were collected for the assessment of hematology parameter: reticulocytes. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
          <units>Percentage of reticulocytes in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 hours post-dose (Day 1), n=4,4,6,5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0012" spread="0.00330"/>
                    <measurement group_id="O2" value="0.0017" spread="0.00310"/>
                    <measurement group_id="O3" value="0.0017" spread="0.00216"/>
                    <measurement group_id="O4" value="0.0000" spread="0.00100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 to Day 14, n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0058" spread="0.00411"/>
                    <measurement group_id="O2" value="0.0014" spread="0.00358"/>
                    <measurement group_id="O3" value="0.0025" spread="0.00333"/>
                    <measurement group_id="O4" value="0.0040" spread="0.00325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Urinalysis Results by Dipstick Method</title>
        <description>Urine samples were collected to assess urine bilirubin, urine occult blood, urine glucose, urine ketones, and urine protein by dipstick test. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameter of urine bilirubin, urine occult blood, urine glucose, urine ketones and urine protein can be read as negative, trace, 1+, 2+ and 3+ indicating proportional concentrations in the urine sample.</description>
        <time_frame>24 hours post-dose (Day 1)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Urinalysis Results by Dipstick Method</title>
          <description>Urine samples were collected to assess urine bilirubin, urine occult blood, urine glucose, urine ketones, and urine protein by dipstick test. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameter of urine bilirubin, urine occult blood, urine glucose, urine ketones and urine protein can be read as negative, trace, 1+, 2+ and 3+ indicating proportional concentrations in the urine sample.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bilirubin, 24 hours post-dose (Day 1), negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin, 24 hours post-dose (Day 1), trace</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin, 24 hours post-dose (Day 1), 1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin, 24 hours post-dose (Day 1), 2+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin, 24 hours post-dose (Day 1), 3+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult Blood, 24 hours post-dose (Day 1), negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult Blood, 24 hours post-dose (Day 1), trace</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult Blood, 24 hours post-dose (Day 1), 1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult Blood, 24 hours post-dose (Day 1), 2+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult Blood, 24 hours post-dose (Day 1), 3+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 24 hours post-dose (Day 1), negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 24 hours post-dose (Day 1), trace</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 24 hours post-dose (Day 1), 1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 24 hours post-dose (Day 1), 2+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 24 hours post-dose (Day 1), 3+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones, 24 hours post-dose (Day 1), negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones, 24 hours post-dose (Day 1), trace</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones, 24 hours post-dose (Day 1), 1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones, 24 hours post-dose (Day 1), 2+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones, 24 hours post-dose (Day 1), 3+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, 24 hours post-dose (Day 1), negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, 24 hours post-dose (Day 1), trace</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, 24 hours post-dose (Day 1), 1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, 24 hours post-dose (Day 1), 2+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, 24 hours post-dose (Day 1), 3+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulse Rate</title>
        <description>Pulse rate was measured in supine position after at least a 5-minute rest. Change from Baseline in pulse rate was evaluated. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
        <time_frame>Baseline (Day 1, Pre-dose); 0.5 hour, 1 hour, 2 hours, 4 hours, 8 hours, 24 hours post-dose (Day 1); and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse Rate</title>
          <description>Pulse rate was measured in supine position after at least a 5-minute rest. Change from Baseline in pulse rate was evaluated. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hour post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="5.85"/>
                    <measurement group_id="O2" value="-0.8" spread="3.42"/>
                    <measurement group_id="O3" value="3.5" spread="8.64"/>
                    <measurement group_id="O4" value="3.6" spread="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="6.98"/>
                    <measurement group_id="O2" value="0.8" spread="6.69"/>
                    <measurement group_id="O3" value="-0.7" spread="3.67"/>
                    <measurement group_id="O4" value="-1.0" spread="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="7.62"/>
                    <measurement group_id="O2" value="-0.4" spread="1.95"/>
                    <measurement group_id="O3" value="-1.8" spread="6.65"/>
                    <measurement group_id="O4" value="1.0" spread="5.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="6.80"/>
                    <measurement group_id="O2" value="11.6" spread="13.67"/>
                    <measurement group_id="O3" value="-1.2" spread="6.40"/>
                    <measurement group_id="O4" value="-0.8" spread="7.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post-dose (Day 1), n=4,4,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="6.90"/>
                    <measurement group_id="O2" value="1.8" spread="5.19"/>
                    <measurement group_id="O3" value="5.7" spread="5.85"/>
                    <measurement group_id="O4" value="8.6" spread="9.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="11.27"/>
                    <measurement group_id="O2" value="3.6" spread="6.50"/>
                    <measurement group_id="O3" value="7.5" spread="7.12"/>
                    <measurement group_id="O4" value="13.0" spread="9.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 to Day 14, n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="14.31"/>
                    <measurement group_id="O2" value="4.4" spread="5.86"/>
                    <measurement group_id="O3" value="5.3" spread="6.25"/>
                    <measurement group_id="O4" value="9.8" spread="8.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Respiratory Rate</title>
        <description>Respiratory rate was measured in supine position after at least a 5-minute rest. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
        <time_frame>Baseline (Day 1, Pre-dose); 0.5 hour, 1 hour, 2 hours, 4 hours, 8 hours and 24 hours post-dose (Day 1); and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Respiratory Rate</title>
          <description>Respiratory rate was measured in supine position after at least a 5-minute rest. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
          <units>Breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hour post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="3.11"/>
                    <measurement group_id="O2" value="-3.4" spread="4.39"/>
                    <measurement group_id="O3" value="-2.2" spread="4.92"/>
                    <measurement group_id="O4" value="0.1" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="1.71"/>
                    <measurement group_id="O2" value="-3.2" spread="5.67"/>
                    <measurement group_id="O3" value="1.8" spread="9.22"/>
                    <measurement group_id="O4" value="0.0" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="2.16"/>
                    <measurement group_id="O2" value="-2.6" spread="2.97"/>
                    <measurement group_id="O3" value="-3.0" spread="4.52"/>
                    <measurement group_id="O4" value="-1.0" spread="4.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="2.08"/>
                    <measurement group_id="O2" value="-2.2" spread="5.63"/>
                    <measurement group_id="O3" value="-2.2" spread="3.54"/>
                    <measurement group_id="O4" value="0.1" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post-dose (Day 1), n=4,4,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="1.63"/>
                    <measurement group_id="O2" value="-0.3" spread="3.50"/>
                    <measurement group_id="O3" value="0.2" spread="2.56"/>
                    <measurement group_id="O4" value="1.1" spread="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="0.96"/>
                    <measurement group_id="O2" value="0.8" spread="2.28"/>
                    <measurement group_id="O3" value="0.3" spread="2.58"/>
                    <measurement group_id="O4" value="-0.1" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 to Day 14, n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.73"/>
                    <measurement group_id="O2" value="-0.4" spread="3.58"/>
                    <measurement group_id="O3" value="2.0" spread="2.28"/>
                    <measurement group_id="O4" value="0.3" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)</title>
        <description>DBP and SBP were measured in supine position after at least a 5-minute rest. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
        <time_frame>Baseline (Day 1, Pre-dose); 0.5 hour, 1 hour, 2 hours, 4 hours, 8 hours and 24 hours post-dose (Day 1); and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)</title>
          <description>DBP and SBP were measured in supine position after at least a 5-minute rest. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
          <units>Millimeters of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DBP, 0.5 hour post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="8.58"/>
                    <measurement group_id="O2" value="-1.0" spread="10.42"/>
                    <measurement group_id="O3" value="-5.0" spread="14.67"/>
                    <measurement group_id="O4" value="-3.3" spread="4.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 1 hour post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="6.22"/>
                    <measurement group_id="O2" value="0.6" spread="8.56"/>
                    <measurement group_id="O3" value="-4.3" spread="9.73"/>
                    <measurement group_id="O4" value="-2.3" spread="3.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 2 hours post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="12.40"/>
                    <measurement group_id="O2" value="1.2" spread="10.55"/>
                    <measurement group_id="O3" value="-5.8" spread="8.80"/>
                    <measurement group_id="O4" value="3.3" spread="5.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 4 hours post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="2.65"/>
                    <measurement group_id="O2" value="3.0" spread="8.37"/>
                    <measurement group_id="O3" value="-2.7" spread="13.22"/>
                    <measurement group_id="O4" value="1.6" spread="6.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 8 hours post-dose (Day 1), n=4,4,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.3" spread="6.65"/>
                    <measurement group_id="O2" value="-6.3" spread="8.66"/>
                    <measurement group_id="O3" value="-10.2" spread="9.15"/>
                    <measurement group_id="O4" value="-1.0" spread="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 24 hours post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.5" spread="7.94"/>
                    <measurement group_id="O2" value="-8.6" spread="9.61"/>
                    <measurement group_id="O3" value="-2.8" spread="10.61"/>
                    <measurement group_id="O4" value="-3.1" spread="8.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 7 to Day 14, n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="7.19"/>
                    <measurement group_id="O2" value="-2.2" spread="6.91"/>
                    <measurement group_id="O3" value="-2.5" spread="11.78"/>
                    <measurement group_id="O4" value="2.8" spread="12.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 0.5 hour post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="12.28"/>
                    <measurement group_id="O2" value="-0.2" spread="12.60"/>
                    <measurement group_id="O3" value="-5.2" spread="6.11"/>
                    <measurement group_id="O4" value="-0.1" spread="5.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 1 hour post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="9.91"/>
                    <measurement group_id="O2" value="3.4" spread="12.68"/>
                    <measurement group_id="O3" value="-2.7" spread="9.37"/>
                    <measurement group_id="O4" value="3.0" spread="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 2 hours post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="15.12"/>
                    <measurement group_id="O2" value="2.0" spread="10.20"/>
                    <measurement group_id="O3" value="-0.7" spread="18.84"/>
                    <measurement group_id="O4" value="2.0" spread="11.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 4 hours post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="19.69"/>
                    <measurement group_id="O2" value="4.2" spread="9.34"/>
                    <measurement group_id="O3" value="6.3" spread="13.03"/>
                    <measurement group_id="O4" value="6.1" spread="13.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 8 hours post-dose (Day 1), n=4,4,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="10.38"/>
                    <measurement group_id="O2" value="3.0" spread="16.57"/>
                    <measurement group_id="O3" value="-5.2" spread="7.63"/>
                    <measurement group_id="O4" value="-4.8" spread="9.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 24 hours post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="4.51"/>
                    <measurement group_id="O2" value="-0.2" spread="14.72"/>
                    <measurement group_id="O3" value="-4.7" spread="11.41"/>
                    <measurement group_id="O4" value="-3.8" spread="14.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 7 to Day 14, n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="21.37"/>
                    <measurement group_id="O2" value="6.0" spread="6.78"/>
                    <measurement group_id="O3" value="-5.8" spread="15.07"/>
                    <measurement group_id="O4" value="-2.1" spread="9.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal Electrocardiogram (ECG) Findings</title>
        <description>12-lead ECGs were obtained at each time point using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and Corrected QT (QTc) intervals. Only those participants who had any abnormal ECG findings are presented. Abnormal ECG findings were categorized as clinically significant (CS) and not clinically significant (NCS) abnormal ECG findings. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
        <time_frame>4 hours and 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Electrocardiogram (ECG) Findings</title>
          <description>12-lead ECGs were obtained at each time point using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and Corrected QT (QTc) intervals. Only those participants who had any abnormal ECG findings are presented. Abnormal ECG findings were categorized as clinically significant (CS) and not clinically significant (NCS) abnormal ECG findings. CS abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal NCS, 4 hours post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal CS, 4 hours post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal NCS, 24 hours post-dose(Day 1), n=3,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal CS, 24 hours post-dose (Day 1), n=3,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal NCS, Day 7 to Day 14, n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal CS, Day 7 to Day 14, n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulse Oximetry Parameter: Percent Oxygen in Blood</title>
        <description>Percent oxygen in blood was measured using pulse oximetry after the participant had rested for at least 5 minutes. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
        <time_frame>Baseline (Day 1, Pre-dose); 0.5 hour, 1 hour, 2 hours, 4 hours, 8 hours and 24 hours post-dose (Day 1); and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse Oximetry Parameter: Percent Oxygen in Blood</title>
          <description>Percent oxygen in blood was measured using pulse oximetry after the participant had rested for at least 5 minutes. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
          <units>Percentage of oxygen in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hour post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="2.30"/>
                    <measurement group_id="O2" value="-1.7" spread="2.77"/>
                    <measurement group_id="O3" value="0.8" spread="2.31"/>
                    <measurement group_id="O4" value="-0.5" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="2.87"/>
                    <measurement group_id="O2" value="-2.1" spread="2.79"/>
                    <measurement group_id="O3" value="-0.3" spread="1.03"/>
                    <measurement group_id="O4" value="-0.9" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="1.91"/>
                    <measurement group_id="O2" value="-0.7" spread="1.99"/>
                    <measurement group_id="O3" value="0.6" spread="1.21"/>
                    <measurement group_id="O4" value="0.9" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="2.21"/>
                    <measurement group_id="O2" value="-1.0" spread="1.87"/>
                    <measurement group_id="O3" value="-0.3" spread="1.96"/>
                    <measurement group_id="O4" value="0.5" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post-dose (Day 1), n=4,4,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="2.50"/>
                    <measurement group_id="O2" value="-0.2" spread="3.58"/>
                    <measurement group_id="O3" value="0.8" spread="2.31"/>
                    <measurement group_id="O4" value="0.4" spread="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours post-dose (Day 1), n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="2.00"/>
                    <measurement group_id="O2" value="-2.3" spread="3.06"/>
                    <measurement group_id="O3" value="2.1" spread="1.60"/>
                    <measurement group_id="O4" value="1.0" spread="3.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 to Day 14, n=4,5,6,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.95"/>
                    <measurement group_id="O2" value="-2.9" spread="2.37"/>
                    <measurement group_id="O3" value="0.5" spread="3.33"/>
                    <measurement group_id="O4" value="0.8" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Positive Immunogenicity Results</title>
        <description>Immunogenicity samples were collected into a serum-separating tube, mixed by gentle inversion 5 times and left to coagulate at room temperature for a minimum of 30 minutes and a maximum of 60 minutes. All samples were first tested for anti-angiotensin converting enzyme type 2 (ACE2) binding antibodies by screening and confirmation assay steps. If post-dose samples were found to be positive for anti-ACE2 binding antibodies, they would have been further characterized for anti-ACE2 neutralizing antibodies. Number of participants with positive immunogenicity results post-dosing are presented.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Immunogenicity Results</title>
          <description>Immunogenicity samples were collected into a serum-separating tube, mixed by gentle inversion 5 times and left to coagulate at room temperature for a minimum of 30 minutes and a maximum of 60 minutes. All samples were first tested for anti-angiotensin converting enzyme type 2 (ACE2) binding antibodies by screening and confirmation assay steps. If post-dose samples were found to be positive for anti-ACE2 binding antibodies, they would have been further characterized for anti-ACE2 neutralizing antibodies. Number of participants with positive immunogenicity results post-dosing are presented.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systemic Renin-Angiotensin System (RAS) Peptides: Angiotensin II, Angiotensin (1-5) and Angiotensin (1-7)</title>
        <description>Blood samples were collected to evaluate systemic RAS peptides: Angiotensin (Ang) II, Ang (1-7) and Ang (1-5). Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
        <time_frame>Baseline (Day 1, Pre-dose); 0.08 hour, 0.5 hour, 1 hour, 2 hours, 4 hours, 8 hours and 24 hours post-dose (Day 1); and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
        <population>Evaluable Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systemic Renin-Angiotensin System (RAS) Peptides: Angiotensin II, Angiotensin (1-5) and Angiotensin (1-7)</title>
          <description>Blood samples were collected to evaluate systemic RAS peptides: Angiotensin (Ang) II, Ang (1-7) and Ang (1-5). Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
          <population>Evaluable Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ang II, 0.08 hour post-dose (Day 1), n=4,5,5,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.143" lower_limit="0.028" upper_limit="0.723"/>
                    <measurement group_id="O2" value="0.185" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75 percentage (%) of the values were below lower limit of quantification.</measurement>
                    <measurement group_id="O3" value="1.020" lower_limit="0.063" upper_limit="16.661"/>
                    <measurement group_id="O4" value="0.254" lower_limit="0.078" upper_limit="0.831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang II, 0.5 hour post-dose (Day 1), n=4,5,5,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.179" lower_limit="0.040" upper_limit="0.792"/>
                    <measurement group_id="O2" value="0.210" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                    <measurement group_id="O3" value="0.500" lower_limit="0.065" upper_limit="3.825"/>
                    <measurement group_id="O4" value="0.211" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang II, 1 hour post-dose (Day 1), n=4,5,5,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.238" lower_limit="0.097" upper_limit="0.582"/>
                    <measurement group_id="O2" value="0.162" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                    <measurement group_id="O3" value="0.420" lower_limit="0.086" upper_limit="2.062"/>
                    <measurement group_id="O4" value="0.235" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang II, 2 hours post-dose (Day 1), n=4,5,5,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.230" lower_limit="0.041" upper_limit="1.280"/>
                    <measurement group_id="O2" value="0.166" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                    <measurement group_id="O3" value="0.393" lower_limit="0.159" upper_limit="0.970"/>
                    <measurement group_id="O4" value="0.211" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang II, 4 hours post-dose (Day 1), n=4,5,5,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.372" lower_limit="0.159" upper_limit="0.872"/>
                    <measurement group_id="O2" value="0.187" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                    <measurement group_id="O3" value="0.398" lower_limit="0.161" upper_limit="0.980"/>
                    <measurement group_id="O4" value="0.387" lower_limit="0.160" upper_limit="0.933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang II, 8 hours post-dose (Day 1), n=4,5,5,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.889" lower_limit="0.148" upper_limit="5.327"/>
                    <measurement group_id="O2" value="0.669" lower_limit="0.249" upper_limit="1.798"/>
                    <measurement group_id="O3" value="0.503" lower_limit="0.311" upper_limit="0.813"/>
                    <measurement group_id="O4" value="0.277" lower_limit="0.080" upper_limit="0.963"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang II, 24 hours post-dose (Day 1), n=4,5,5,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.329" lower_limit="0.692" upper_limit="7.836"/>
                    <measurement group_id="O2" value="1.372" lower_limit="0.462" upper_limit="4.070"/>
                    <measurement group_id="O3" value="0.763" lower_limit="0.267" upper_limit="2.184"/>
                    <measurement group_id="O4" value="0.939" lower_limit="0.186" upper_limit="4.751"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang II, Day 7 to Day 14, n=4,5,5,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.625" lower_limit="0.084" upper_limit="31.300"/>
                    <measurement group_id="O2" value="2.380" lower_limit="0.703" upper_limit="8.063"/>
                    <measurement group_id="O3" value="0.616" lower_limit="0.115" upper_limit="3.307"/>
                    <measurement group_id="O4" value="1.826" lower_limit="0.399" upper_limit="8.354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang (1-5), 0.08 hour post-dose (Day 1), n=4,5,4,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.884" lower_limit="0.505" upper_limit="7.026"/>
                    <measurement group_id="O2" value="4.696" lower_limit="1.303" upper_limit="16.923"/>
                    <measurement group_id="O3" value="2.222" lower_limit="0.774" upper_limit="6.373"/>
                    <measurement group_id="O4" value="2.982" lower_limit="1.360" upper_limit="6.535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang (1-5), 0.5 hour post-dose (Day 1), n=4,5,4,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.342" lower_limit="0.435" upper_limit="12.622"/>
                    <measurement group_id="O2" value="5.325" lower_limit="1.427" upper_limit="19.873"/>
                    <measurement group_id="O3" value="2.895" lower_limit="1.206" upper_limit="6.950"/>
                    <measurement group_id="O4" value="3.187" lower_limit="1.303" upper_limit="7.797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang (1-5), 1 hour post-dose (Day 1), n=4,5,4,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.427" lower_limit="0.414" upper_limit="14.225"/>
                    <measurement group_id="O2" value="4.263" lower_limit="1.463" upper_limit="12.418"/>
                    <measurement group_id="O3" value="2.572" lower_limit="0.775" upper_limit="8.539"/>
                    <measurement group_id="O4" value="3.264" lower_limit="1.134" upper_limit="9.396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang (1-5), 2 hours post-dose (Day 1), n=4,5,4,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.269" lower_limit="0.344" upper_limit="14.945"/>
                    <measurement group_id="O2" value="3.499" lower_limit="1.377" upper_limit="8.890"/>
                    <measurement group_id="O3" value="3.423" lower_limit="0.698" upper_limit="16.789"/>
                    <measurement group_id="O4" value="2.463" lower_limit="0.982" upper_limit="6.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang (1-5), 4 hours post-dose (Day 1), n=4,5,4,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.442" lower_limit="0.344" upper_limit="17.340"/>
                    <measurement group_id="O2" value="2.740" lower_limit="1.245" upper_limit="6.033"/>
                    <measurement group_id="O3" value="3.513" lower_limit="0.750" upper_limit="16.459"/>
                    <measurement group_id="O4" value="2.717" lower_limit="1.033" upper_limit="7.146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang (1-5), 8 hours post-dose (Day 1), n=4,5,4,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.365" lower_limit="1.094" upper_limit="17.420"/>
                    <measurement group_id="O2" value="4.125" lower_limit="0.716" upper_limit="23.775"/>
                    <measurement group_id="O3" value="6.691" lower_limit="0.812" upper_limit="55.117"/>
                    <measurement group_id="O4" value="4.882" lower_limit="1.581" upper_limit="15.072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang (1-5), 24 hours post-dose (Day 1), n=4,5,4,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.397" lower_limit="0.879" upper_limit="6.536"/>
                    <measurement group_id="O2" value="3.701" lower_limit="1.413" upper_limit="9.690"/>
                    <measurement group_id="O3" value="2.573" lower_limit="0.403" upper_limit="16.426"/>
                    <measurement group_id="O4" value="5.117" lower_limit="1.910" upper_limit="13.712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang (1-5), Day 7 to Day 14, n=4,5,3,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.469" lower_limit="0.714" upper_limit="3.020"/>
                    <measurement group_id="O2" value="2.110" lower_limit="0.775" upper_limit="5.744"/>
                    <measurement group_id="O3" value="0.548" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                    <measurement group_id="O4" value="1.642" lower_limit="0.781" upper_limit="3.450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang (1-7), 0.08 hour post-dose (Day 1), n=4,5,5,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.252" lower_limit="0.366" upper_limit="13.855"/>
                    <measurement group_id="O2" value="4.392" lower_limit="1.405" upper_limit="13.732"/>
                    <measurement group_id="O3" value="3.465" lower_limit="1.025" upper_limit="11.719"/>
                    <measurement group_id="O4" value="1.817" lower_limit="0.969" upper_limit="3.405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang (1-7), 0.5 hour post-dose (Day 1), n=4,5,5,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.943" lower_limit="0.335" upper_limit="25.843"/>
                    <measurement group_id="O2" value="4.935" lower_limit="1.383" upper_limit="17.617"/>
                    <measurement group_id="O3" value="2.242" lower_limit="0.639" upper_limit="7.865"/>
                    <measurement group_id="O4" value="2.205" lower_limit="1.260" upper_limit="3.859"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang (1-7), 1 hour post-dose (Day 1), n=4,5,5,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.002" lower_limit="0.318" upper_limit="28.319"/>
                    <measurement group_id="O2" value="3.494" lower_limit="1.438" upper_limit="8.490"/>
                    <measurement group_id="O3" value="2.362" lower_limit="0.542" upper_limit="10.291"/>
                    <measurement group_id="O4" value="1.780" lower_limit="0.783" upper_limit="4.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang (1-7), 2 hours post-dose (Day 1), n=4,5,5,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.311" lower_limit="0.161" upper_limit="33.222"/>
                    <measurement group_id="O2" value="4.025" lower_limit="1.393" upper_limit="11.630"/>
                    <measurement group_id="O3" value="3.471" lower_limit="0.651" upper_limit="18.500"/>
                    <measurement group_id="O4" value="1.949" lower_limit="1.012" upper_limit="3.756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang (1-7), 4 hours post-dose (Day 1), n=4,5,5,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.350" lower_limit="0.230" upper_limit="48.748"/>
                    <measurement group_id="O2" value="3.115" lower_limit="1.349" upper_limit="7.190"/>
                    <measurement group_id="O3" value="3.623" lower_limit="0.679" upper_limit="19.331"/>
                    <measurement group_id="O4" value="1.818" lower_limit="0.715" upper_limit="4.623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang (1-7), 8 hours post-dose (Day 1), n=4,5,5,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.910" lower_limit="0.654" upper_limit="36.845"/>
                    <measurement group_id="O2" value="3.517" lower_limit="0.635" upper_limit="19.477"/>
                    <measurement group_id="O3" value="6.002" lower_limit="0.762" upper_limit="47.289"/>
                    <measurement group_id="O4" value="4.229" lower_limit="1.433" upper_limit="12.477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang (1-7), 24 hours post-dose (Day 1), n=4,5,5,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.423" lower_limit="0.618" upper_limit="18.944"/>
                    <measurement group_id="O2" value="4.096" lower_limit="1.430" upper_limit="11.730"/>
                    <measurement group_id="O3" value="2.812" lower_limit="0.503" upper_limit="15.732"/>
                    <measurement group_id="O4" value="7.095" lower_limit="2.426" upper_limit="20.752"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang (1-7), Day 7 to Day 14, n=4,5,5,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.190" lower_limit="0.684" upper_limit="2.073"/>
                    <measurement group_id="O2" value="1.904" lower_limit="0.596" upper_limit="6.089"/>
                    <measurement group_id="O3" value="0.925" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                    <measurement group_id="O4" value="1.932" lower_limit="1.111" upper_limit="3.362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulmonary Wedge RAS Peptides: Angiotensin II, Angiotensin (1-5) and Angiotensin (1-7)</title>
        <description>Blood samples were collected to evaluate pulmonary wedge RAS peptides: Ang II, Ang (1-5) and Ang (1-7). Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value.</description>
        <time_frame>Baseline (Day 1, Pre-dose); 1 hour, 2 hours and 4 hours post-dose (Day 1)</time_frame>
        <population>Evaluable Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulmonary Wedge RAS Peptides: Angiotensin II, Angiotensin (1-5) and Angiotensin (1-7)</title>
          <description>Blood samples were collected to evaluate pulmonary wedge RAS peptides: Ang II, Ang (1-5) and Ang (1-7). Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value.</description>
          <population>Evaluable Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ang II, 1 hour post-dose (Day 1), n=4,4,4,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.270" lower_limit="0.059" upper_limit="1.244"/>
                    <measurement group_id="O2" value="0.190" lower_limit="0.025" upper_limit="1.475"/>
                    <measurement group_id="O3" value="0.394" lower_limit="0.046" upper_limit="3.414"/>
                    <measurement group_id="O4" value="0.369" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang II, 2 hours post-dose (Day 1), n=4,4,4,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.310" lower_limit="0.068" upper_limit="1.419"/>
                    <measurement group_id="O2" value="0.193" lower_limit="0.025" upper_limit="1.476"/>
                    <measurement group_id="O3" value="0.505" lower_limit="0.147" upper_limit="1.738"/>
                    <measurement group_id="O4" value="0.369" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang II, 4 hours post-dose (Day 1), n=4,4,3,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.332" lower_limit="0.089" upper_limit="1.240"/>
                    <measurement group_id="O2" value="0.191" lower_limit="0.025" upper_limit="1.475"/>
                    <measurement group_id="O3" value="0.183" lower_limit="0.038" upper_limit="0.879"/>
                    <measurement group_id="O4" value="0.420" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang (1-5), 1 hour post-dose (Day 1), n=4,4,4,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.985" lower_limit="0.279" upper_limit="31.931"/>
                    <measurement group_id="O2" value="3.313" lower_limit="0.892" upper_limit="12.310"/>
                    <measurement group_id="O3" value="2.709" lower_limit="0.792" upper_limit="9.269"/>
                    <measurement group_id="O4" value="1.834" lower_limit="0.743" upper_limit="4.528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang (1-5), 2 hours post-dose (Day 1), n=4,4,3,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.443" lower_limit="0.282" upper_limit="42.025"/>
                    <measurement group_id="O2" value="4.621" lower_limit="0.803" upper_limit="26.600"/>
                    <measurement group_id="O3" value="5.246" lower_limit="1.386" upper_limit="19.859"/>
                    <measurement group_id="O4" value="1.562" lower_limit="0.566" upper_limit="4.312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang (1-5), 4 hours post-dose (Day 1), n=4,4,3,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.373" lower_limit="0.401" upper_limit="14.050"/>
                    <measurement group_id="O2" value="3.213" lower_limit="0.757" upper_limit="13.646"/>
                    <measurement group_id="O3" value="5.239" lower_limit="1.565" upper_limit="17.541"/>
                    <measurement group_id="O4" value="1.472" lower_limit="0.575" upper_limit="3.768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang (1-7), 1 hour post-dose (Day 1), n=4,4,4,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.840" lower_limit="0.353" upper_limit="22.846"/>
                    <measurement group_id="O2" value="4.150" lower_limit="0.912" upper_limit="18.880"/>
                    <measurement group_id="O3" value="2.993" lower_limit="0.356" upper_limit="25.136"/>
                    <measurement group_id="O4" value="1.558" lower_limit="0.969" upper_limit="2.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang (1-7), 2 hours post-dose (Day 1), n=4,4,4,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.376" lower_limit="0.279" upper_limit="40.910"/>
                    <measurement group_id="O2" value="3.792" lower_limit="0.878" upper_limit="16.368"/>
                    <measurement group_id="O3" value="4.476" lower_limit="0.612" upper_limit="32.754"/>
                    <measurement group_id="O4" value="1.589" lower_limit="0.830" upper_limit="3.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ang (1-7), 4 hours post-dose (Day 1), n=4,4,3,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.857" lower_limit="0.362" upper_limit="22.550"/>
                    <measurement group_id="O2" value="3.151" lower_limit="0.849" upper_limit="11.693"/>
                    <measurement group_id="O3" value="8.521" lower_limit="0.733" upper_limit="99.048"/>
                    <measurement group_id="O4" value="1.693" lower_limit="0.818" upper_limit="3.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic RAS Peptide: Angiotensin II/Angiotensin (1-7) Ratio at Indicated Time Points</title>
        <description>Blood samples were collected to assess systemic RAS peptides: Angiotensin II and Angiotensin (1-7). Data for angiotensin II/angiotensin (1-7) ratio is presented. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
        <time_frame>0.08 hour, 0.5 hour, 1 hour, 2 hours, 4 hours, 8 hours and 24 hours post-dose (Day 1) and one sample between Day 7 to Day 14 (follow up visit)</time_frame>
        <population>Evaluable Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic RAS Peptide: Angiotensin II/Angiotensin (1-7) Ratio at Indicated Time Points</title>
          <description>Blood samples were collected to assess systemic RAS peptides: Angiotensin II and Angiotensin (1-7). Data for angiotensin II/angiotensin (1-7) ratio is presented. Assessment of follow up visit was conducted between any day of Days 7 to 14.</description>
          <population>Evaluable Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.08 hour post-dose (Day 1), n=4,5,5,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.752" lower_limit="0.175" upper_limit="3.239"/>
                    <measurement group_id="O2" value="0.463" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                    <measurement group_id="O3" value="1.450" lower_limit="0.313" upper_limit="6.711"/>
                    <measurement group_id="O4" value="0.843" lower_limit="0.491" upper_limit="1.447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 hour post-dose (Day 1), n=4,5,5,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.718" lower_limit="0.186" upper_limit="2.779"/>
                    <measurement group_id="O2" value="0.468" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                    <measurement group_id="O3" value="1.097" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                    <measurement group_id="O4" value="0.590" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post-dose (Day 1), n=4,5,5,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.937" lower_limit="0.351" upper_limit="2.504"/>
                    <measurement group_id="O2" value="0.509" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                    <measurement group_id="O3" value="0.875" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                    <measurement group_id="O4" value="0.794" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose (Day 1), n=4,5,5,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.174" lower_limit="0.539" upper_limit="2.559"/>
                    <measurement group_id="O2" value="0.455" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                    <measurement group_id="O3" value="0.558" lower_limit="0.150" upper_limit="2.077"/>
                    <measurement group_id="O4" value="0.657" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose (Day 1), n=4,5,5,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.312" lower_limit="0.571" upper_limit="3.011"/>
                    <measurement group_id="O2" value="0.659" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                    <measurement group_id="O3" value="0.540" lower_limit="0.136" upper_limit="2.144"/>
                    <measurement group_id="O4" value="1.283" lower_limit="0.530" upper_limit="3.102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours post-dose (Day 1), n=4,5,5,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.139" lower_limit="0.623" upper_limit="7.339"/>
                    <measurement group_id="O2" value="2.093" lower_limit="0.778" upper_limit="5.625"/>
                    <measurement group_id="O3" value="0.412" lower_limit="0.083" upper_limit="2.055"/>
                    <measurement group_id="O4" value="0.439" lower_limit="0.181" upper_limit="1.062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours post-dose (Day 1), n=4,5,5,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.041" lower_limit="2.416" upper_limit="26.757"/>
                    <measurement group_id="O2" value="3.682" lower_limit="1.929" upper_limit="7.030"/>
                    <measurement group_id="O3" value="1.335" lower_limit="0.908" upper_limit="1.965"/>
                    <measurement group_id="O4" value="0.946" lower_limit="0.435" upper_limit="2.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 to Day 14, n=4,5,5,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.132" lower_limit="1.204" upper_limit="216.087"/>
                    <measurement group_id="O2" value="13.742" lower_limit="3.829" upper_limit="49.326"/>
                    <measurement group_id="O3" value="3.278" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                    <measurement group_id="O4" value="6.156" lower_limit="2.618" upper_limit="14.479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Wedge RAS Peptide: Angiotensin II/Angiotensin (1-7) Ratio at Indicated Time Points</title>
        <description>Blood samples were collected to assess pulmonary wedge RAS peptides: Angiotensin II and Angiotensin (1-7). Data for angiotensin II/angiotensin (1-7) ratio is presented.</description>
        <time_frame>1 hour, 2 hours and 4 hours post-dose (Day 1)</time_frame>
        <population>Evaluable Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Wedge RAS Peptide: Angiotensin II/Angiotensin (1-7) Ratio at Indicated Time Points</title>
          <description>Blood samples were collected to assess pulmonary wedge RAS peptides: Angiotensin II and Angiotensin (1-7). Data for angiotensin II/angiotensin (1-7) ratio is presented.</description>
          <population>Evaluable Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour post-dose (Day 1), n=4,4,4,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.888" lower_limit="0.275" upper_limit="2.866"/>
                    <measurement group_id="O2" value="0.443" lower_limit="0.108" upper_limit="1.821"/>
                    <measurement group_id="O3" value="0.620" lower_limit="0.058" upper_limit="6.650"/>
                    <measurement group_id="O4" value="0.789" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose (Day 1), n=4,4,4,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.858" lower_limit="0.253" upper_limit="2.908"/>
                    <measurement group_id="O2" value="0.493" lower_limit="0.116" upper_limit="2.096"/>
                    <measurement group_id="O3" value="0.531" lower_limit="0.117" upper_limit="2.403"/>
                    <measurement group_id="O4" value="0.774" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose (Day 1), n=4,4,3,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.085" lower_limit="0.478" upper_limit="2.462"/>
                    <measurement group_id="O2" value="0.587" lower_limit="0.172" upper_limit="2.003"/>
                    <measurement group_id="O3" value="0.148" lower_limit="0.012" upper_limit="1.759"/>
                    <measurement group_id="O4" value="0.826" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Biomarkers: N-terminal Pro B-type Natriuretic Peptide (NT Pro-BNP)</title>
        <description>Blood samples were collected at specific time points to evaluate NT pro-BNP, a biomarker of disease activity. NT-pro-BNP is a biomarker of cardiac stress or ventricular workload and decreases as a result of reduced force of contraction if pulmonary blood pressure is reduced. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value.</description>
        <time_frame>Baseline (Day 1, Pre-dose); 2 hours, 4 hours and 24 hours post-dose (Day 1)</time_frame>
        <population>Evaluable Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Biomarkers: N-terminal Pro B-type Natriuretic Peptide (NT Pro-BNP)</title>
          <description>Blood samples were collected at specific time points to evaluate NT pro-BNP, a biomarker of disease activity. NT-pro-BNP is a biomarker of cardiac stress or ventricular workload and decreases as a result of reduced force of contraction if pulmonary blood pressure is reduced. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value.</description>
          <population>Evaluable Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.034" lower_limit="0.955" upper_limit="1.119"/>
                    <measurement group_id="O2" value="1.005" lower_limit="0.842" upper_limit="1.199"/>
                    <measurement group_id="O3" value="0.923" lower_limit="0.795" upper_limit="1.071"/>
                    <measurement group_id="O4" value="1.015" lower_limit="0.841" upper_limit="1.224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.025" lower_limit="0.924" upper_limit="1.138"/>
                    <measurement group_id="O2" value="1.042" lower_limit="0.852" upper_limit="1.276"/>
                    <measurement group_id="O3" value="0.944" lower_limit="0.795" upper_limit="1.120"/>
                    <measurement group_id="O4" value="1.074" lower_limit="0.840" upper_limit="1.373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.606" lower_limit="0.253" upper_limit="1.453"/>
                    <measurement group_id="O2" value="0.896" lower_limit="0.481" upper_limit="1.670"/>
                    <measurement group_id="O3" value="0.703" lower_limit="0.430" upper_limit="1.151"/>
                    <measurement group_id="O4" value="0.810" lower_limit="0.539" upper_limit="1.217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nitrite, Nitrate and Endogenous Nitrite (Biomarkers of Nitric Oxide [NO])</title>
        <description>Blood samples were collected at specific time points to evaluate levels of nitrite, nitrate and endogenous nitrite (En. nitrite) (biomarkers of NO). Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value.</description>
        <time_frame>Baseline (Day 1, Pre-dose); 2 hours, 4 hours and 24 hours post-dose (Day 1)</time_frame>
        <population>Evaluable Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nitrite, Nitrate and Endogenous Nitrite (Biomarkers of Nitric Oxide [NO])</title>
          <description>Blood samples were collected at specific time points to evaluate levels of nitrite, nitrate and endogenous nitrite (En. nitrite) (biomarkers of NO). Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value.</description>
          <population>Evaluable Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nitrite, 2 hours post-dose (Day 1), n=4,4,5,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.246" lower_limit="0.440" upper_limit="3.533"/>
                    <measurement group_id="O2" value="1.029" lower_limit="0.870" upper_limit="1.216"/>
                    <measurement group_id="O3" value="0.530" lower_limit="0.145" upper_limit="1.931"/>
                    <measurement group_id="O4" value="0.858" lower_limit="0.797" upper_limit="0.923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nitrite, 4 hours post-dose (Day 1), n=4,4,5,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.760" lower_limit="0.635" upper_limit="0.910"/>
                    <measurement group_id="O2" value="0.992" lower_limit="0.749" upper_limit="1.312"/>
                    <measurement group_id="O3" value="0.679" lower_limit="0.420" upper_limit="1.096"/>
                    <measurement group_id="O4" value="0.770" lower_limit="0.654" upper_limit="0.907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nitrite, 24 hours post-dose (Day 1), n=4,4,4,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.038" lower_limit="0.898" upper_limit="1.199"/>
                    <measurement group_id="O2" value="1.146" lower_limit="1.044" upper_limit="1.259"/>
                    <measurement group_id="O3" value="0.667" lower_limit="0.245" upper_limit="1.814"/>
                    <measurement group_id="O4" value="0.914" lower_limit="0.605" upper_limit="1.381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nitrate, 2 hours post-dose (Day 1), n=4,4,5,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.251" lower_limit="0.432" upper_limit="3.623"/>
                    <measurement group_id="O2" value="1.025" lower_limit="0.862" upper_limit="1.218"/>
                    <measurement group_id="O3" value="0.485" lower_limit="0.108" upper_limit="2.177"/>
                    <measurement group_id="O4" value="0.836" lower_limit="0.768" upper_limit="0.910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nitrate, 4 hours post-dose (Day 1), n=4,4,5,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.739" lower_limit="0.595" upper_limit="0.917"/>
                    <measurement group_id="O2" value="0.977" lower_limit="0.700" upper_limit="1.362"/>
                    <measurement group_id="O3" value="0.655" lower_limit="0.395" upper_limit="1.086"/>
                    <measurement group_id="O4" value="0.762" lower_limit="0.649" upper_limit="0.895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nitrate, 24 hours post-dose (Day 1), n=4,4,4,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.017" lower_limit="0.853" upper_limit="1.212"/>
                    <measurement group_id="O2" value="1.149" lower_limit="1.049" upper_limit="1.259"/>
                    <measurement group_id="O3" value="0.641" lower_limit="0.222" upper_limit="1.854"/>
                    <measurement group_id="O4" value="0.911" lower_limit="0.597" upper_limit="1.390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>En. nitrite, 2 hours post-dose (Day 1), n=4,4,5,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.099" lower_limit="0.798" upper_limit="1.512"/>
                    <measurement group_id="O2" value="2.036" lower_limit="0.309" upper_limit="13.411"/>
                    <measurement group_id="O3" value="1.171" lower_limit="0.878" upper_limit="1.563"/>
                    <measurement group_id="O4" value="0.975" lower_limit="0.647" upper_limit="1.469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>En. nitrite, 4 hours post-dose (Day 1), n=4,4,5,8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.245" lower_limit="0.665" upper_limit="2.330"/>
                    <measurement group_id="O2" value="2.819" lower_limit="0.079" upper_limit="100.021"/>
                    <measurement group_id="O3" value="1.329" lower_limit="0.643" upper_limit="2.747"/>
                    <measurement group_id="O4" value="0.820" lower_limit="0.466" upper_limit="1.443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>En. nitrite, 24 hours post-dose (Day 1), n=4,4,4,7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.290" lower_limit="0.543" upper_limit="3.063"/>
                    <measurement group_id="O2" value="1.399" lower_limit="0.503" upper_limit="3.894"/>
                    <measurement group_id="O3" value="1.289" lower_limit="0.501" upper_limit="3.316"/>
                    <measurement group_id="O4" value="1.271" lower_limit="0.614" upper_limit="2.634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Biomarker: Cardiac Troponin-I</title>
        <description>Blood samples were collected at specific time points to assess cardiac troponin I. Cardiac troponin I is a biomarker of cardiac stress. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value.</description>
        <time_frame>Baseline (Day 1, Pre-dose); 2 hours, 4 hours and 24 hours post-dose (Day 1)</time_frame>
        <population>Evaluable Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Biomarker: Cardiac Troponin-I</title>
          <description>Blood samples were collected at specific time points to assess cardiac troponin I. Cardiac troponin I is a biomarker of cardiac stress. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value.</description>
          <population>Evaluable Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.565" lower_limit="0.660" upper_limit="3.714"/>
                    <measurement group_id="O2" value="1.320" lower_limit="0.824" upper_limit="2.114"/>
                    <measurement group_id="O3" value="1.585" lower_limit="0.657" upper_limit="3.822"/>
                    <measurement group_id="O4" value="1.414" lower_limit="0.761" upper_limit="2.628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.968" lower_limit="0.543" upper_limit="7.131"/>
                    <measurement group_id="O2" value="1.149" lower_limit="0.782" upper_limit="1.688"/>
                    <measurement group_id="O3" value="1.695" lower_limit="0.592" upper_limit="4.856"/>
                    <measurement group_id="O4" value="2.030" lower_limit="1.064" upper_limit="3.873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.316" lower_limit="0.549" upper_limit="3.154"/>
                    <measurement group_id="O2" value="1.000" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                    <measurement group_id="O3" value="1.000" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                    <measurement group_id="O4" value="1.000" lower_limit="NA" upper_limit="NA">NA indicates confidence interval could not be estimated as more than 75% of the values were below lower limit of quantification.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of GSK2586881</title>
        <description>Blood samples were collected at indicated time points for evaluation of Cmax. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (Day 1) and 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose (Day 1)</time_frame>
        <population>Pharmacokinetic population comprised of participants in the Safety Population for whom a pharmacokinetic sample was obtained and analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of GSK2586881</title>
          <description>Blood samples were collected at indicated time points for evaluation of Cmax. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic population comprised of participants in the Safety Population for whom a pharmacokinetic sample was obtained and analyzed.</population>
          <units>Micrograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5159" spread="37.0"/>
                    <measurement group_id="O2" value="4.0229" spread="37.4"/>
                    <measurement group_id="O3" value="8.9701" spread="26.1"/>
                    <measurement group_id="O4" value="14.8042" spread="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Cmax (Tmax) of GSK2586881</title>
        <description>Blood samples were collected at indicated time points for evaluation of tmax. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (Day 1) and 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose (Day 1)</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cmax (Tmax) of GSK2586881</title>
          <description>Blood samples were collected at indicated time points for evaluation of tmax. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08333" lower_limit="0.0833" upper_limit="0.1333"/>
                    <measurement group_id="O2" value="0.16667" lower_limit="0.0667" upper_limit="0.5000"/>
                    <measurement group_id="O3" value="0.10000" lower_limit="0.0667" upper_limit="0.5500"/>
                    <measurement group_id="O4" value="0.13333" lower_limit="0.0833" upper_limit="0.6333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-t]) of GSK2586881</title>
        <description>Blood samples were collected at indicated time points for evaluation of AUC(0-t). Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (Day 1) and 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose (Day 1)</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-t]) of GSK2586881</title>
          <description>Blood samples were collected at indicated time points for evaluation of AUC(0-t). Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours*micrograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.941" spread="53.6"/>
                    <measurement group_id="O2" value="17.874" spread="30.9"/>
                    <measurement group_id="O3" value="46.789" spread="16.3"/>
                    <measurement group_id="O4" value="68.042" spread="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) of GSK2586881</title>
        <description>Blood samples were collected at indicated time points for evaluation of AUC(0-inf). Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (Day 1) and 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose (Day 1)</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) of GSK2586881</title>
          <description>Blood samples were collected at indicated time points for evaluation of AUC(0-inf). Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Hours*micrograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">The terminal elimination phase could not be identified from the concentration-time profile for any participants in the 0.1 mg/kg treatment group over the study period; hence, AUC(0-inf) could not be estimated.</measurement>
                    <measurement group_id="O2" value="25.26" spread="7.7"/>
                    <measurement group_id="O3" value="52.46" spread="20.0"/>
                    <measurement group_id="O4" value="76.87" spread="42.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Last Observed Quantifiable Concentration (Ct) of GSK2586881</title>
        <description>Blood samples were collected at indicated time points for evaluation of Ct. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (Day 1) and 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose (Day 1)</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Last Observed Quantifiable Concentration (Ct) of GSK2586881</title>
          <description>Blood samples were collected at indicated time points for evaluation of Ct. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>Micrograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2563" spread="22.8"/>
                    <measurement group_id="O2" value="0.3327" spread="54.4"/>
                    <measurement group_id="O3" value="0.4800" spread="44.9"/>
                    <measurement group_id="O4" value="0.6380" spread="54.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of the Last Quantifiable Concentration (Tlast) of GSK2586881</title>
        <description>Blood samples were collected at indicated time points for evaluation of tlast. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (Day 1) and 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose (Day 1)</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of the Last Quantifiable Concentration (Tlast) of GSK2586881</title>
          <description>Blood samples were collected at indicated time points for evaluation of tlast. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.000" lower_limit="4.20" upper_limit="8.47"/>
                    <measurement group_id="O2" value="24.000" lower_limit="8.18" upper_limit="24.25"/>
                    <measurement group_id="O3" value="24.017" lower_limit="23.73" upper_limit="24.15"/>
                    <measurement group_id="O4" value="24.117" lower_limit="23.97" upper_limit="24.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Clearance (CL) of GSK2586881</title>
        <description>Blood samples were collected at indicated time points for evaluation of CL. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (Day 1) and 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose (Day 1)</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Clearance (CL) of GSK2586881</title>
          <description>Blood samples were collected at indicated time points for evaluation of CL. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Liters per hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">The terminal elimination phase could not be identified from the concentration-time profile for any participants in the 0.1 mg/kg treatment group over the study period; hence, plasma clearance could not be estimated.</measurement>
                    <measurement group_id="O2" value="0.5838" spread="10.1"/>
                    <measurement group_id="O3" value="0.6207" spread="16.8"/>
                    <measurement group_id="O4" value="0.8170" spread="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution of GSK2586881</title>
        <description>Blood samples were collected at indicated time points for evaluation of apparent volume of distribution. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (Day 1) and 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose (Day 1)</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution of GSK2586881</title>
          <description>Blood samples were collected at indicated time points for evaluation of apparent volume of distribution. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">The terminal elimination phase could not be identified from the concentration-time profile for any participants in the 0.1 mg/kg treatment group over the study period; hence, apparent volume of distribution could not be estimated.</measurement>
                    <measurement group_id="O2" value="6.443" spread="2.4"/>
                    <measurement group_id="O3" value="6.593" spread="20.5"/>
                    <measurement group_id="O4" value="8.084" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Phase Half-life (t1/2) of GSK2586881</title>
        <description>Blood samples were collected at indicated time points for evaluation of t1/2. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Pre-dose (Day 1) and 0.08, 0.5, 1, 2, 4, 8 and 24 hours post-dose (Day 1)</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Phase Half-life (t1/2) of GSK2586881</title>
          <description>Blood samples were collected at indicated time points for evaluation of t1/2. Pharmacokinetic parameters were calculated by standard non-compartmental analysis.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">The terminal elimination phase could not be identified from the concentration-time profile for any participants in the 0.1 mg/kg treatment group over the study period; hence, t1/2 could not be estimated.</measurement>
                    <measurement group_id="O2" value="7.651" spread="7.7"/>
                    <measurement group_id="O3" value="7.362" spread="23.2"/>
                    <measurement group_id="O4" value="6.858" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Cardiac Index (CI)</title>
        <description>Cardiac index (CI) was measured using thermodilution. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value.</description>
        <time_frame>Baseline (Day 1, Pre-dose); 1 hour, 2 hours and 4 hours post-dose (Day 1)</time_frame>
        <population>Evaluable Population. Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2586881 0.1 mg/kg</title>
            <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O2">
            <title>GSK2586881 0.2 mg/kg</title>
            <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O3">
            <title>GSK2586881 0.4 mg/kg</title>
            <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
          <group group_id="O4">
            <title>GSK2586881 0.8 mg/kg</title>
            <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cardiac Index (CI)</title>
          <description>Cardiac index (CI) was measured using thermodilution. Baseline was defined as the latest pre-dose assessment (Day 1) with a non-missing value, including those from unscheduled visits. Change from Baseline was measured as ratio of post-dose visit value to Baseline value.</description>
          <population>Evaluable Population. Only those participants with data available at the specified time points were analyzed.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.045" lower_limit="0.874" upper_limit="1.248"/>
                    <measurement group_id="O2" value="1.076" lower_limit="0.947" upper_limit="1.223"/>
                    <measurement group_id="O3" value="1.084" lower_limit="0.766" upper_limit="1.533"/>
                    <measurement group_id="O4" value="0.990" lower_limit="0.948" upper_limit="1.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.021" lower_limit="0.816" upper_limit="1.278"/>
                    <measurement group_id="O2" value="1.029" lower_limit="0.951" upper_limit="1.113"/>
                    <measurement group_id="O3" value="0.926" lower_limit="0.719" upper_limit="1.193"/>
                    <measurement group_id="O4" value="1.020" lower_limit="0.948" upper_limit="1.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post-dose (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.107" lower_limit="0.801" upper_limit="1.530"/>
                    <measurement group_id="O2" value="1.128" lower_limit="0.941" upper_limit="1.352"/>
                    <measurement group_id="O3" value="0.889" lower_limit="0.740" upper_limit="1.068"/>
                    <measurement group_id="O4" value="1.000" lower_limit="0.933" upper_limit="1.072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Non-SAEs and SAEs were reported from start of study treatment and up to Day 28</time_frame>
      <desc>Non-SAEs and SAEs were reported for Safety Population. Adverse events were presented treatment-wise.</desc>
      <group_list>
        <group group_id="E1">
          <title>GSK2586881 0.1 mg/kg</title>
          <description>Participants received a single IV dose of 0.1 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
        </group>
        <group group_id="E2">
          <title>GSK2586881 0.2 mg/kg</title>
          <description>Participants received a single IV dose of 0.2 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
        </group>
        <group group_id="E3">
          <title>GSK2586881 0.4 mg/kg</title>
          <description>Participants received a single IV dose of 0.4 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
        </group>
        <group group_id="E4">
          <title>GSK2586881 0.8 mg/kg</title>
          <description>Participants received a single IV dose of 0.8 mg/kg GSK2586881 and were followed up till 28 days post-dose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

